Bifidobacterium bifidum VPro 51 and Reduced IBS Symptoms

• Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial.

  • 2020-07
  • RCT · n = 443
  • The Lancet Gastroenterology & Hepatology 5(7)
  • • V. Andresen
    • J. Gschossmann
    • P. Layer

  • PubMed: 32277872
  • DOI: 10.1016/S2468-1253(20)30056-X

  10 Insights on

  • Reduced IBS Symptoms

  • High evidence
  • Large Human Trial
  • Highly Cited
  • Rigorous Journal

  The composite primary endpoint was reached by 74 (34%) of 221 patients in the B bifidum HI-MIMBb75 group compared with 43 (19%) of 222 in the placebo group (risk ratio 1·7, 95% CI 1·3-2·4; p=0·0007).

  Effect

  Beneficial

  Effect size

  Moderate

  Significant

  Yes